A Phase II Study with Orteronel as Monotherapy in Patients with Metastatic Breast Cancer (MBC) that Expresses the Androgen Receptor (AR)

Type of Cancer
Breast Oncology

Site
Bethesda

Sponsor
Sarah Cannon Research Institute

Protocol Number
BRE203

To Learn More Call
201-510-0910